Literature DB >> 1505652

Characterization of a family with moderate hypercholesterolemia and binding defective low density lipoprotein.

A L Catapano1, A Corsini, M Mazzotti, A Granata, P Uboldi, F M Maggi, L Romano, C Romano, S Fantappiè, R Fumagalli.   

Abstract

Familial defective apolipoprotein B-100 (FDB) is a genetic disorder presenting with hypercholesterolemia and abnormal low density lipoprotein (LDL) that binds poorly to LDL receptors. This disease appears to be caused by a mutation in the apo B gene. In the present study thirteen members of a family with moderate hypercholesterolemia (250-350 mg/dl) were investigated. Biochemical studies on cultured skin fibroblasts ruled out classical familial hypercholesterolemia (receptor deficiency). LDL from nine affected members displayed, in an "in vitro" cell binding assay, a reduced affinity (2.5 fold) for the receptor, and had normal electrophoretic mobility, size and chemical composition. Lp(a) levels in family members were comparable to those present in normolipidemics and lower than those observed in primary hypercholesterolemia. The disorder is transmitted over three generations as an autosomal codominant trait and all the affected members are heterozygotes and hypercholesterolemic.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1505652     DOI: 10.1007/bf00145346

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  21 in total

1.  Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100.

Authors:  C Y Yang; S H Chen; S H Gianturco; W A Bradley; J T Sparrow; M Tanimura; W H Li; D A Sparrow; H DeLoof; M Rosseneu
Journal:  Nature       Date:  1986 Oct 23-29       Impact factor: 49.962

Review 2.  Causes of high blood cholesterol.

Authors:  S M Grundy; G L Vega
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

3.  Isolation, characterization, and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a).

Authors:  V W Armstrong; A K Walli; D Seidel
Journal:  J Lipid Res       Date:  1985-11       Impact factor: 5.922

4.  Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases.

Authors:  A Tybjaerg-Hansen; J Gallagher; J Vincent; R Houlston; P Talmud; A M Dunning; M Seed; A Hamsten; S E Humphries; N B Myant
Journal:  Atherosclerosis       Date:  1990-01       Impact factor: 5.162

5.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.

Authors:  J W McLean; J E Tomlinson; W J Kuang; D L Eaton; E Y Chen; G M Fless; A M Scanu; R M Lawn
Journal:  Nature       Date:  1987 Nov 12-18       Impact factor: 49.962

6.  Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100.

Authors:  L F Soria; E H Ludwig; H R Clarke; G L Vega; S M Grundy; B J McCarthy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

7.  Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia.

Authors:  A Corsini; P Roma; D Sommariva; R Fumagalli; A L Catapano
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

8.  A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine.

Authors:  L M Powell; S C Wallis; R J Pease; Y H Edwards; T J Knott; J Scott
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

9.  Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding.

Authors:  T L Innerarity; K H Weisgraber; K S Arnold; R W Mahley; R M Krauss; G L Vega; S M Grundy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 10.  Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia.

Authors:  T L Innerarity; R W Mahley; K H Weisgraber; T P Bersot; R M Krauss; G L Vega; S M Grundy; W Friedl; J Davignon; B J McCarthy
Journal:  J Lipid Res       Date:  1990-08       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.